VIA
KRYS icon

Virtus Investment Advisers’s Krystal Biotech KRYS Stock Holding History

Virtus Investment Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
3,657
+208
+6% +$62.1K 0.32% 142
2026
Q1 		$891K Buy
3,449
+657
+24% +$175K 0.25% 151
2025
Q4 		$688K Sell
2,792
-375
-12% -$78.9K 0.19% 173
2025
Q3 		$559K Hold
3,167
– – 0.16% 193
2025
Q2 		$435K Buy
3,167
+1,099
+53% +$161K 0.15% 210
2025
Q1 		$373K Buy
+2,068
New +$348K 0.1% 221

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Virtus Investment Advisers's KRYS Position: Q2 2026 in Review

Virtus Investment Advisers increased its Krystal Biotech (KRYS) stake by 6% in Q2 2026, buying an estimated $62.1K and bringing the position to 3,657 shares worth $1.36M. The position accounts for 0.32% of the portfolio, ranked #142.

Virtus Investment Advisers first reported a position in KRYS in Q1 2025 and has held it in 6 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Virtus Investment Advisers held 3,657 shares of Krystal Biotech worth $1.36M as of Q2 2026.
  • Virtus Investment Advisers bought 208 Krystal Biotech shares in Q2 2026, an estimated $62.1K.
  • Krystal Biotech made up 0.32% of Virtus Investment Advisers's portfolio in Q2 2026, its #142 holding.
  • Virtus Investment Advisers first reported a position in Krystal Biotech in Q1 2025 and has held it in 6 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.